Navigation Links
Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose

Trial Convincingly Proves Functionality in Humans of CTI's Programmable, Pulsatile, Passive Transdermal Drug Delivery Device - ChronoDose

BASEL, Switzerland and TRENTON, N.J., May 03, 2007 /PRNewswire/ -- Chrono Therapeutics Inc. (CTI) announced today the successful completion of its first phase human clinical trial of its programmable, pulsatile, passive transdermal drug/device combination product: ChronoDose(TM). CTI intends to publish this clinical data in leading scientific and medical journals by year end.

CLINICAL STUDY DESIGN

The trial was conducted between February and April 2007 at the University Hospital Basel, Switzerland, Division of Clinical Pharmacology and Toxicology. Georgios Imanidis, PhD, of the University of Basel was the Principal Investigator on behalf of CTI.

This study was an open, randomized, three period, single-center, dose- escalation study. Thirty-six independent human transdermal tests were conducted on male volunteers using wristwatch-like ChronoDose(TM) devices. The trial successfully proved the efficacy of the device on human subjects using its model drug compound. The dose escalation trial showed statistically significant modulation and control of the dosing profiles. Using low, medium and high concentrations, for 16 hours, the model drug permeated each subject's skin on multiple occasions, resulting in clear and distinct peaks and troughs of therapeutically effective and well-targeted blood plasma concentration levels. A non-compartmental and compartmental model based analysis of pharmacokinetics will be utilized. Local and systemic tolerability of the model drug after its transdermal administration was better than planned.

Dr. Georgios Imanidis commented, "CTI has for the first time in transdermal drug delivery history successfully completed a significant human trial with a passive, automated and programmable multiple dosing transdermal device syste
'"/>




Page: 1 2 3

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
9. Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
Post Your Comments:
(Date:3/1/2015)... March 1, 2015  USPlabs has notified the ... and states that media reports saying that a ... On Saturday, February 28, 2015, the Center for ... Notification on the contamination of a dietary supplement ... to below as "OEP") with a prescription drug ...
(Date:2/27/2015)... , Feb. 27, 2015 Pharmaceutical and biotech ... multiple products for the same indication. This can be ... want to prevent one of their brands from gaining ... According to recent research by benchmarking firm, Best Practices, ... independent brands rather than together as part of a ...
(Date:2/27/2015)... , Feb. 27, 2015 WuXi PharmaTech ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... therapy designation from the U.S. FDA for ibalizumab (TMB355). ... if it is intended, alone or in combination with ...
Breaking Medicine Technology:OEP Product Is Counterfeit 2New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2
... 13, 2011 BD (Becton, Dickinson and Company) (NYSE: ... a subsidiary of Waste Management, Inc. (NYSE: ... sharps waste from hospitals and other healthcare facilities.  The ... Solution, an innovative service that will recycle medical sharps ...
... Healthcare Financial Management Association (HFMA) has recognized the ... ("SIS") as once again consistently meeting the "Peer ... offerings as part of the annual evaluation process ... HFMA Peer Reviewed designation.  ...
Cached Medicine Technology:BD and Waste Management Launch Initiative to Recycle Medical Sharps 2BD and Waste Management Launch Initiative to Recycle Medical Sharps 3BD and Waste Management Launch Initiative to Recycle Medical Sharps 4Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 2Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 3
(Date:3/1/2015)... March 01, 2015 Indiana Fiber ... Service Provider, announces NewWays Networking, LLC (NewWays) selected ... working with IFN, NewWays is well positioned to ... demand for Internet bandwidth in rural parts of ... According to Cory Childs IFN Enterprise Sales Manager, ...
(Date:3/1/2015)... The Barrel Mill ” was featured on NewsWatch as part ... the latest and coolest technology products and services available to ... expert, conducted the review and shared with viewers how this ... Home Distillation of Alcohol, it's understood that oak is essential ... product that’ll help anyone achieve a barrel aged alcohol without ...
(Date:3/1/2015)... (PRWEB) February 28, 2015 CrossFit Attollo is ... they are offering a special discount to new members. ... up for a three month contract will receive their fourth ... individually would cost members $440. The three month contract ... month, and then the fourth month comes in at only ...
(Date:2/28/2015)... 2015 In recent years Medical Marijuana has ... physicians as a way for them to expand their patient ... as medicine. Since the FDA still lists Cannabis as a ... to licensed physicians that can help guide them when ... Malka in Santa Cruz, CA is a leader in ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
Breaking Medicine News(10 mins):Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3
... due to non-recurring event in 2007, net loss stable ... Canadian dollars unless otherwise noted), BELLEVILLE, ON, Nov. ... research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results for ... 30, 2007. "We are also focused on the ...
... Reduce Debt and Enhance Financial Flexibility To Fund ... ... Balance, Inc.,(Nasdaq: SMBL ) today announced its results for the third ... 2007, the Company,reported net sales of approximately $42 million and a net ...
... HALL, N.C., EXTON, Pa. and SAN DIEGO, Nov. ... southeastern US,provider of oncology equipment sales and service, ... alliance with Radiology Oncology Systems, Inc.,(ROS), an oncology ... Acceletronics, Inc., a US provider of oncology equipment ...
... and ... Product Portfolio, LA JOLLA, Calif., ... today announced that,it has raised $33.9 million in a Series B ... round were Frazier,Healthcare Ventures and Alloy Ventures, along with founding investor ...
... Charged with Illegally Distributing over 12 Million Narcotic ... United States,Attorney Matt M. Dummermuth announced today that ... distribute controlled substances through an,Internet pharmacy and with ... in an Indictment filed today in United States ...
... Nov. 8 Cash Technologies, Inc.,(Amex: TQ ) ... American,Stock Exchange (the "Exchange" or "AMEX") notified Cash Tech ... certain of the Exchange,s continued,listing standards as set forth ... Guide). Specifically, Cash Tech is not in compliance with ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9Health News:Bioniche Reports Fiscal 2008 First Quarter 10Health News:Bioniche Reports Fiscal 2008 First Quarter 11Health News:Smart Balance Announces Third Quarter 2007 Results 2Health News:Smart Balance Announces Third Quarter 2007 Results 3Health News:Smart Balance Announces Third Quarter 2007 Results 4Health News:Smart Balance Announces Third Quarter 2007 Results 5Health News:Smart Balance Announces Third Quarter 2007 Results 6Health News:Smart Balance Announces Third Quarter 2007 Results 7Health News:Smart Balance Announces Third Quarter 2007 Results 8Health News:Smart Balance Announces Third Quarter 2007 Results 9Health News:Smart Balance Announces Third Quarter 2007 Results 10Health News:Smart Balance Announces Third Quarter 2007 Results 11Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 2Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2Health News:Cash Technologies Discusses AMEX Listing Requirements 2Health News:Cash Technologies Discusses AMEX Listing Requirements 3Health News:Cash Technologies Discusses AMEX Listing Requirements 4
... RayShield X-Drape combines full 0.25 mm ... Fiber sterile drape material that can ... field between the clinician and the ... the clinician must be in very ...
... Pacemaker Follow-Up Solution makes convenience and ... our Cardiac Monitoring Center, qualified professionals ... seven days a week for Pacemaker ... time they experience a problem or ...
... introduction, the PROTG® GPS™ Self-Expanding ... has delivered on a commitment ... confidence. PROTG GPS Stents take ... level by adding tantalum markers ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Medicine Products: